Ferric carboxymaltose versus ferric gluconate in hemodialysis patients: Reduction of erythropoietin dose in 4 years of follow-up

• Asıl Yazarlar: Antonio Lacquaniti (Yazar), Patrizio Pasqualetti (Yazar), Teresa Casuscelli di Tocco (Yazar), Susanna Campo (Yazar), Stefania Rovito (Yazar), Maurizio Bucca (Yazar), Antonino Ragusa (Yazar), Paolo Monardo (Yazar)
• Materyal Türü: Kitap
• Baskı/Yayın Bilgisi: The Korean Society of Nephrology, 2020-09-01T00:00:00Z.
• Konular: article
• Online Erişim: Connect to this object online.

Background : : Ferric carboxymaltose (FCM) is a parenteral, dextran-free iron formulation designed to overcome the limitations of existing iron preparations. The main aim of this study was to retrospectively examine results obtained from a long period of FCM therapy in hemodialysis patients who have...